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Our focus is the identiﬁcation, characterisation and functional analysis of different MLL fusions. In gen-
eral, MLL fusion proteins are encoded by large cDNA cassettes that are difﬁcult to transduce into haema-
topoietic stem cells. This is due to the size limitations of the packaging process of those vector-encoded
RNAs into retro- or lentiviral particles. Here, we present our efforts in establishing a universal vector
system to analyse different MLL fusions. The universal cloning system was embedded into the backbone
of the Sleeping Beauty transposable element. This transposon has no size limitation and displays no
integration preference, thereby avoiding the integration into active genes or their promoter regions.
We utilised this novel system to test different MLL fusion alleles (MLL-NEBL, NEBL-MLL, MLL-LASP1,
LASP1-MLL, MLL-MAML2, MAML2-MLL, MLL-SMAP1 and SMAP1-MLL) in appropriate cell lines. Stable
cell lines were analysed for their growth behaviour, focus formation and colony formation capacity
and ectopic Hoxa gene transcription. Our results show that only 1/4 tested direct MLL fusions, but 3/4
tested reciprocal MLL fusions exhibit oncogenic functions. From these pilot experiments, we conclude
that a systematic analysis of more MLL fusions will result in a more differentiated picture about the
oncogenic capacity of distinct MLL fusions.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is anopenaccessarticleunder theCCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Chromosomal translocations of the human MLL gene are
associated with different types of human leukemias (ALL: acute
lymphoblastic leukemia; AML: acute myeloid leukemia; MLL:
mixed-lineage leukemia), and so far about 80 MLL fusions have
been described in the literature [1,2]. Despite the chromosomal
translocation t(1;11)(q21;q23), resulting in the expression of the
MLL-AF1Q fusion protein and displaying a very good clinical prog-
nosis (EFS = 0,92), all other MLL fusions give a dismal prognosis
(EFS = 0.11–0.50) [3]. This indicates that these MLL fusion proteins
are probably highly potent in initiating and maintaining the corre-
sponding leukemia disease phenotype.
By contrast, our understanding about the pathological func-
tion(s) of MLL fusion proteins is based on experiments performed
with a handful of these chimeric proteins. Only the MLL fusions
deriving from t(4;11), t(9;11), t(10;11), t(11;19) and few others
have been functionally investigated. The fusion proteins – derivingfrom the aforementioned MLL translocations – trigger very similar
downstream events, namely the ability to bind and activate
endogenous AF4/AF5 complexes (also named superelongation
complexes), or the direct activation of RNA Polymerase II, as does
the AF4-MLL fusion protein [4]. This causes an increase in mRNA
levels and ectopic/extended histone methylation signatures
(H3K4 and H3K79) [5–7]. Furthermore, these 4 MLL gene fusions
account for more than 90% of ALL cases (infant, childhood and
adult) and about 50% of AML cases (infant, childhood and adult).
However, for the vast majority of MLL fusions (n = 76), the
underlying pathological mechanism(s) are unclear. Fusion partner
genes encode proteins that are barely investigated or are even of
cytosolic origin. Thus, potential oncogenic functions of these
proteins – when fused to MLL and translocated into the nucleus
– must be deemed artiﬁcial.
One general obstacle when dealing with MLL fusions is the large
size of their open reading frames, which is contrasted with the
limitations for packaging these constructs into retro- or lentiviral
backbones. This hampers the in vivo analysis for most known
MLL fusions. On the other hand, in vitro systems allow for impor-
tant conclusions to be drawn when used appropriately and in a
systematic fashion. Therefore, we decided to establish a universal
system that allows for rapid and functional characterisation of
different MLL fusions in order to screen for interesting candidates
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purposes, we used the Sleeping Beauty transposon system as
vector backbone which can be stably integrated in low copy num-
bers into mammalian cell lines by co-transfection with Sleeping
Beauty transposase. Stable cell lines can be rapidly selected and
functional analyses performed in parallel to investigate the func-
tions of different MLL fusions under identical conditions.
Here, we present the results of our study in which we analysed
4 different MLL translocations. The results of our study suggest that
reciprocal MLL fusions should be put into the focus of scientiﬁc
research.
Materials and methods
Construction of a universal vector system using the Sleeping Beauty backbone
As summarised in Fig. 1A, universal vector backbones were cloned. For direct
MLL fusions, we designed a vector that contains a constitutive promoter followed
by SﬁI(A)-NcoI restriction endonuclease sites. Following these 2 restriction sites, a
bona ﬁde AUG start codon and a Flag-Tag, fused in frame to MLL exons 1–9, was
added to the vector. The last exon, MLL exon 9, is ﬂanked by a short portion of
the germline MLL intron 9 sequence that ends with a multiple cloning site consist-
ing of XhoI, BstBI and SﬁI(B) restriction sites. Corresponding cDNA fragments of par-
ter genes (gene of interest, GOI) were cloned with a region of their germline intron
with all exons (cDNA) up to and including their natural stop codon. Both primers
used to amplify these partner cDNAs contained restriction recognition sites for XhoI
and BstBI, respectively. After digests with these enzymes, the hybrid gDNA/cDNAFig. 1. (A) Scheme of the universal sleeping beauty vector constructs. ITR: inverted term
phosphoglycerate kinase promoter; GFP/RFP: green/red ﬂuorescent protein; rtTA: reve
gene; GOI: gene of interest; MLL 14–38; coding sequence of MLL exons 14–37; Tag: F
comparing to a single copy locus on chromosome 19 (left bar); underlined: co-transfe
experiments to qualitatively analyse correct splicing of transcripts deriving from all tes
indicated in basepairs.fragments were cloned into the XhoI and BstBI restriction sites of the universal vec-
tor. Since the complete cassette is ﬂanked by two different SﬁI sites (A and B), the
cassette (MLL-X) can be mobilised without promoter and polyA signal sequence.
Similarly, a vector for reciprocal MLL fusions was designed. It contains also a
constitutive promotor followed by SﬁI(A)-NcoI-AvrII restriction endonuclease sites.
Behind this multiple cloning site a short portion of the germline MLL intron 13 is
fused to MLL exons 14–37, with no stop codon. Instead, the MLL sequence is
followed by a Flag-tag and a stop codon prior to the BstBI-SﬁI(B) restriction sites.
Partner cDNAs (GOI) were ampliﬁed with oligonucleotides that exhibit a short track
of 50-NTR nucleotides and the NcoI recognition site in combination with an oligonu-
cleotide, comprising the sequence of the last exon, a short portion of the following
intron and the AvrII recognition site. The ampliﬁed sequences were cloned
upstream of the MLL sequence by using NcoI-AvrII digests. Here, the complete
cassette (X-MLL) could also be mobilised by an SﬁI digest.
The original Sleeping Beauty (SB) vector backbone [8] was modiﬁed with a
TRE2-promoter, two consecutive SﬁI sites (A and B) followed by an poly A signal.
This inducible cassette is separated from the PGK promotor which drives transla-
tion of a polycistronic mRNA cassette that encodes a ﬂuorescent protein, the reverse
Tet repressor protein (M2S rtTA) and either a hygromycine (MLL-X) or puromycine
resistance protein (X-MLL). All 3 reading frames were separated by T2A peptide
sequences.
These 2 different SB vector backbones were used to clone the different MLL
fusion genes with Sﬁ1(A/B) cassettes. All direct MLL fusions (MLL-LASP1, MLL-NEBL,
MLL-MAML2 and MLL-SMAP1) were cloned into the GFP-expressing vector (TCZH),
while all reciprocal MLL fusions (LASP1-MLL, NEBL-MLL, MAML2-MLL and SMAP1-
MLL) were cloned into the RFP-expressing one (TCTP). This allowed us to study all
these constructs alone or the combination of both.
A human mutant RAS⁄ protein (G12V) served as positive control. The RAS⁄ gene
was cloned into the TCZH vector. Additionally, we clonedMLL exons 14–37 without
any fused partner gene sequence into the TCTP vector. The MLL⁄ protein is naturallyinal repeats; Pr/TetPr: promoter/Tet-promoter; pA: poly-A signal sequence; PGK:
rse tetracycline transactivator, HYGRO/PURO: hygromycine/puromycin resistance
lag-tag. (B) Quantiﬁcation of integrated Sleeping Beauty vector copy numbers by
cted cells were investigated for the copy numbers of both constructs. (C) RT-PCR
ted constructs; black lanes below: co-transfected cells; sizes of all amplimers are
Fig. 2. Hoxa gene transcriptional proﬁling experiments. All cell lines were tested for
changes in their Hoxa7, Hoxa9 and Hoxa10 transcription. RT-PCR (displayed) and Q-
PCR experiments (not displayed) revealed no signiﬁcant changes in the tested cell
lines.
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12 borderline, and exhibits a bona ﬁde AUG start codon localised within MLL exon
18 [9]. The resulting MLL⁄ protein (227 KDa) has been demonstrated to be
expressed at the protein level and is properly processed by Taspase1.
Transfection of cells
In order to establish stable cell lines from all aforementioned constructs (n = 8),
all SB vector constructs were co-transfected with low amounts (50 ng) of the SB
transposase vector SB100X [10]. FuGENE-transfections into MEF cells were carried
out as recommended by the manufacturer. Twenty-four hours after transfection,
cells were subjected either to Hygromycin (300 lg/ml), Puromycin (1 lg/ml) or
both. Selection was carried out for 3–7 days and terminated when virtually all cells
were emitting the expected green or red light derived from their corresponding
reporter genes. Cells were cultivated for 4 weeks without selection medium and
the stability of the transfected vector constructs were monitored. In all cases, the
transfected constructs remained stable, expressing either GFP or RFP as a surrogate
marker.
RT and QRT-PCR experiments
The transgenes were induced by applying 1 lg/ml Doxycycline to the cell cul-
ture medium. After 48 h, total RNA was isolated and cDNA syntheses were per-
formed. The following oligonucleotides were used for RT-PCR analyses: MLLex9-
F: 50-GCCTCAGCCACCTACTA CAG-30 , MLLex14-R: 50-ATGACACAGTGAGAAATCAT-
GAGA-30 , NEBLex3-F: 50-GGCAGA TACACCTGAAAATCTTCGCCTGA-30 , NEBLex4-R:
50-CAGGAGTGTCCGTGACGATGCT GAAG-30 , LASP1ex6-F: 50-AGCCGGTGGCCCA
GTCCTAT-30 , LASP1ex7-R: 50-TCGATCT GCTGCACGTTGAC-30 , MAML2ex1-F: 50-AGC
CCCACCGCCCCCACCAGACTAT-30 , MAML2ex2-R: 50-GTCTGCTTCTTTCCCATCAAT
TGC-30 , SMAP1ex6-F2: 50-CCAGAAAAGC CGGCAAAACCACTTA-30 , SMAP1ex7-R:
50-TTTTTAGGCTCCAGTTGCTGATCTTTCTTC-30 . Resulting PCR amplicons were sub-
jected to DNA sequencing analysis to validate all splice events were correctly
performed. For murine HoxA gene transcript analyses, we used the following
oligonucleotides: Hoxa7-F: 50-ACGCGCTTTTTAGCAAATATACG-30 , Hoxa7-R: 50-GG
GTGCAAAGGAGCAAGAAG-30 . Hoxa9-F: 50-CCGAACACCCCGACTTCA-30 , Hoxa9-R:
50-TTCCACGAGGCACCAAACA-30 , Hoxa10-F: 50-CACAGGCCACTTTCGTGTTCTT-30 and
Hoxa10-R: 50-TTGTCCGCAGCATCGTAGAG-30 .
CCK-8 assays
The Cell Counting Kit-8 (Dojindo, Munich, Germany) contains a water soluble
Tetrazolium-salt (WST-8) which can be reduced by dehydrogenases in living cells
to an orange-coloured Formazan that can be photometrically measured. All assays
were performed in 96-well plates where 5  2000 cells were seeded for each inves-
tigation. Measurements were made after 0, 24, 48, 72 and 96 h by adding 10 ll CCK-
8 substrate to the wells. Cells were incubated for 2 h in the CO2-incubator (37 C,
95% humidiﬁed, 5% CO2) and activity of dehydrogenase was measured at 450 nm
in an ELISA-Reader MR5000 (Dynatech, Rückersdorf, Germany). Negative controls
consisted of untransfected cells and the medium alone. All experiments were
carried out in triplicates.
Softagar colony formation assays
A 4% low melting point agarose solution was sterilized and then used to pro-
duce a bottom agarose layer (0.7%) containing DMEM medium supplemented with
5% calf serum (CS), 0.02 mM L-Glutamin (L-Gln), 1 U/ml Penicillin/Streptomycin,
0.01 mM Natriumpyruvat and 2 lg/ml Doxycycline. The top agarose layer (0.3%)
contains DMEM supplemented with 5% FCS (fetal calf serum), 5% CS, 0.02 mM L-
Gln, 1 U/ml Penicillin/Streptomycin and 0.01 mM Natriumpyruvat and 2 lg/ml
Doxycycline (FCGAP medium). All cells were incubated in a CO2-incubator (37 C,
95% humidiﬁed, 5% CO2). Every 7 days, 0.5 ml fresh FCGAP medium was added.
After 3 weeks, all cells were incubated with 0.5 ml of a INT (Iodonitro tetrazolium-
chloride)-solution (1 mg/ml) and incubated overnight in the incubator. All experi-
ments were carried out in triplicates. Within an experiment, three approaches
were run for each cell line. All pictures were imported into the ImageJ program
and colonies larger than 15 pixel were counted to remove artifacts. As a positive
control, we included RAS⁄ and the MLL⁄ protein.
Focus formation assays
All stably transfected cell lines were seeded in 6 mm dishes (1  104 cells; n = 3)
and grown in high glucose DMEM medium that contained 10% FCS, 1% 2 mM L-Gln,
1% 100U/ml Penicillin/Streptomycin. Cell growth was carried out in the absence or
presence of 1 lg/ml doxycyline for either 8 or 15 days. All dishes were then ﬁxed
with 3 ml 2% formaline for 10 min, before 1 ml of crystal violet solution was added.
All dishes were rinsed several times with sterile water and dried before photo-
graphs were taken from each dish. As positive control, we used RAS⁄ and the MLL⁄
protein.Results
Transfection was carried out in MEF cells which were subse-
quently selected in antibiotic (Pyromycin, Hygromycin or both)
to create stable cell lines.
First, integration efﬁciency was validated by genomic qPCR
experiments, which were normalised to a single copy locus.
Integration efﬁciency was in the range of 1–10 transgene copies
per cell (Fig. 1B). Therefore, we concluded that we can compare
the data of each set of MLL fusions, because we had no strong dis-
crepancy in copy numbers, as they deviate at a maximum of ±2
copies.
Splice events of all our constructs were investigated by RT-PCR
experiments followed by DNA sequencing. After induction of trans-
genes for 48 h, we performed RT-PCR experiments to validate cor-
rect splicing. PCR amplicons were subjected to DNA sequencing
analysis in order to conﬁrm a correct fusion of the open reading
frames. As shown in Fig. 1C, the introns in all 8 constructs were
spliced out and all reading frames were correctly fused, regardless
whether the constructs were tested from single- or co-transfected
cells.
MLL fusions are characterised by their unique ability to enhance
the transcription of HOXA genes in human cells. As shown in Fig. 2,
we were not able to see any clear changes of Hoxa clusters in MEF
cells when compared to the untransfected cells. Even Q-PCR exper-
iments could not reveal any clear changes (data not shown). From
these data we concluded that an ectopic Hoxa gene activation
could not be induced, either by the direct nor by the reciprocal
MLL fusions tested here. This may indicate that MLL fusion protein
– not docking to the endogenous AF4/AF5 complex (superelonga-
tion complex) – may not be able to change HOXA gene patterns.
Next, we investigated the growth behaviour of single and dou-
ble transfected cell lines. For this purpose we used the CCK-8 assay,
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used as a surrogate marker for cell growth and viability. Fig. 3A
summarises our results obtained with the stable MEF cell lines.
As shown in the ﬁrst panel, RAS⁄ expressing cells displayed a slight
growth advantage after 4 days. Growth/viability was also
enhanced when MLL⁄ was expressed. The next two panels summa-
rise the data obtained with single transfected cells (MLL-X or
X-MLL) and the last panel displays the effect in the presence of
both fusion proteins. Except for MLL-MAML2, the direct MLL
fusions (MLL-NEBL, MLL-LASP1 and MLL-SMAP1) displayed a bet-
ter cell growth when compared to the control. However, the
observed growth rates were lower than in RAS⁄ or MLL⁄ expressing
cells. With the exception of SMAP1-MLL, the reciprocal MLL fusions
displayed a strong growth enhancement, with higher values than
the positive controls. This effect diminished, however, when both
fusion proteins are expressed concomitantly in the same cell. Only
the co-LASP1 and co-MAML2 cell still displayed a slightly
enhanced growth behaviour.
To evaluate anchorage-independent cell growth, colony forma-
tion assays were carried out. Cell lines were seeded in softagar and
dishes were stained after day 21. The pictures obtained from these
dishes were subsequently analysed by the ImageJ program. Colony
formation was evident in all dishes in varying sizes. Therefore, we
focussed only on larger colonies (see Fig. 3B). In addition we
deﬁned a discriminator (mean between negative and positive con-
trols): a number below that borderline was deﬁned as negative,
while a number above this borderline was deﬁned as a positive
result. Based on these assumptions, we obtained a positive score
in this assay only for RAS⁄, MLL⁄, MLL-SMAP1, NEBL-MLL, LASP1-
MLL and the co-LASP1 cells. All others were scored negatively or
were not signiﬁcantly classiﬁable. Cells expressing MLL-MAML2,
MAML2-MLL or both constructs were consistently negative in this
assay, with scores similar to the untransfected or mock-transfected
cells.Fig. 3. (A) CCK-8 assays to monitor cell growth and viability. All data are displayed for M
lines). Data were separated to display the control experiments (MEF, MEF with MLL⁄ and R
represent the data obtained in three independent experiments. Visible bars represent sta
foci/dish. Colonies were counted when their size exceeded 15 pixel on the individual phFocus formation experiments characteristically give the ﬁrst
level of evidence for oncogenic behaviour of mutated or variant
proteins. Cell growth of non-malignant cells is inhibited in these
assays and enter quiescense after conﬂuency is reached, while
oncogenic cells grow into the 3rd dimension and form foci. Here,
we investigated this phenomenon for our cell lines in 60 mm
dishes and monitored their loss-of-contact inhibition after 8 and
15 days post-induction with Doxycyline.
We ﬁrst observed foci after 8 days with cells expressing the
RAS⁄ protein, while none of the 4 tested direct MLL fusions nor
the vector control showed any effect (Fig. 4A, left panel). By con-
trast, when we analysed the 4 different reciprocal MLL fusions,
we observed foci after 8 days in NEBL-MLL cells and MAML2-MLL
cells (Fig. 4B, left panel). In cells co-expressing both reciprocal
MLL fusions, only the co-MAML2 cells displayed focus formation
(Fig. 4C, left panel). After 15 days, the picture became more clear.
Besides RAS⁄, only MLL-SMAP1 was able to induce foci formation,
while none of the other MLL-X constructs displayed such a pheno-
type (Fig. 4A, right panel). Oppositely, the reciprocal NEBL-MLL,
LASP1-MLL, MAML2-MLL and MLL⁄ displayed focus formation,
while SMAP1-MLL did not (Fig. 4B, right panel). In addition, all
co-transfected cells displayed focus formation activity after day
15 (Fig. 4C, right panel). This is not surprising because at least
one of each tested construct was scoring positive. It also indicated
that the observed ‘‘loss of contact inhibition’’ is a dominant pheno-
type. To our surprise, expression of the MLL⁄ protein also caused
focus formation, indicating that the N-terminal truncated MLL
protein by itself may exhibit/activate oncogenic functions.Discussion
In the last decade, our laboratory has identiﬁed a large series of
direct and reciprocal MLL fusions. So far, 79 direct MLL fusionsEFs and MEFs containing the corresponding empty vectors (TCTP and TCZH; green
AS⁄), MLL-X constructs, X-MLL constructs and co-transfected cells. Displayed values
ndard deviations. (B) Colony formation capacity of all tested cell lines. Displayed are
otographs (n = 3).
Fig. 4. Sizes of all pictures are identical and indicated in the ﬁrst row of pictures (scale for 200 lm). (A) Focus formation of direct MLL fusions (MLL-X) at day 8 and 15. Top:
positive RAS control. Bottom: mock- and untransfected controls. (B) Focus formation of reciprocal MLL fusions (X-MLL) at day 8 and 15. Top: positive MLL⁄ control. Bottom:
mock- and untransfected controls. (C) Focus formation of co-transfected MLL fusions (MLL-X and X-MLL) at day 8 and 15.
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been described by our group [2]. Most of these MLL fusions were
never tested in functional experiments.
Here, we present data for 4 MLL fusions that were recurrently
identiﬁed in leukemia patients. We have chosen NEBL and LASP1
because both belong to the same Nebulette gene family and both
were found to be fused in a reciprocal fashion with the MLL gene
in AML patients [11,12]. Both proteins are cytosolic LIM domainproteins with a length of 270 and 261 amino acids, respectively
(the LIM domain is localised at the N-terminus, while the C-termi-
nus exhibits a SH3 domain), and known to regulate/modulate the
actin cytoskeleton via binding to SRC kinase. In addition we were
interested in MAML2 that was diagnosed as a MLL fusion partner
gene in therapy-related, secondary AML and T-ALL patients
[13,14]. MAML2 belongs to a family of coactivators for the NOTCH
signalling pathway. The protein has a length of 1.153 amino acids
Fig. 4 (continued)
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repeats of the -Secretase cleaved NOTCH receptor (NICD). Within
the nucleus, MAML2 forms a complex with NICD and other nuclear
coactivators to mediate transcription of NOTCH target genes. Of
interest, fusions of MAML2 have already been described for
salivary gland carcinomas, or more generally in mucoepidermoid
carcinomas (MEC), where MAML2 is reciprocally fused with MECT1
(Mucoepidermoid Carcinoma Translocated 1) [15]. Finally, we
investigated SMAP1 as a prototype for the many fusion partners
found in AML patients [16]. SMAP1 has a length of 468 amino acids
and encodes a small GTPase that is localised in the outer mem-
brane of stromal cells [17]. SMAP1 regulates ARF proteins (ADP-
ribosylation factors) and is involved in the regulation of Clathrin-
mediated endocytotic processes [18,19]. An overexpression of
SMAP1 causes a downregulation of surface receptors like E-cad-
herin, Transferrin and cKIT receptor. By contrast, SMAP1 knock-
out mice develop MDS or AML, indicating that a loss-of-function
is presumably associated with leukemia development [20].
Beside these fusions, we were curious about testing a disrupted
MLL allele that is frequently generated in complex MLL rearrange-
ments (20% of all investigated patients). Such truncated MLL
alleles derive from a reciprocal MLL fusion that does not allow to
encode an in-frame fusion protein or in other words, a ‘‘incompat-
ible gene fusions’’ (80%), Of interest, all these ‘‘incompatible gene
fusions’’ are able to express the MLL⁄ protein. This is due to the fact
that theMLL gene contain a cryptic promoter at the MLL intron 11/
MLL exon 12 borderline that is enhanced by MLL intron 12
sequences [9]. This results in the production of the 227 kDa MLL⁄
protein that exhibits about half of the BD domain, the fourth
extended PHD domain, the FYRN interaction domain, the TAD
domain, the FYRC interaction domain and the SET domain (H3K4
HMT).
Here, we have successfully generated a universal vector system
to analyse direct and reciprocal MLL fusion genes. This vector
system has several beneﬁts over conventional systems, because
expression of transgenes can be induced by Doxycycline, while a
constitutive expression of ﬂuorescent proteins and selection
marker allows to trace the transfected cells. Selection of stably
integrated vectors took between 3 and 7 days only. By using these
stable cell lines, we attempted to dissect certain functions of fusion
proteins that are derived from their transgenes: (1) cell growth/
viability; (2) Hoxa gene expression; (3) colony formation in soft
agar and (4) focus formation capacity. Investigating cell growth/
viability is difﬁcult due to issues in differentiating between prolif-
eration and apoptosis. However, these experiments overcome
some of these issues and reveals that the expression of direct
MLL fusions seems to be dominant over growth promoting activi-
ties exerted by the reciprocal MLL fusions. This might be explained
by recent ﬁndings, where the steady-state amount of direct MLLfusions is responsible for either growth promotion or inhibition
[21]. The picture changed when we analysed colony formation
and focus formation capacity. LASP1-MLL seems to exert a domi-
nant colony formation phenotype that could not be suppressed
by MLL-LASP1. MLL-SMAP1, NEBL-MLL and MLL⁄ scored all weakly
positive, but the two MAML2 constructs remained negative in this
assay.
Results obtained in focus formation experiments were the
strongest indicator for oncogenic capacity. Here, MLL-SMAP1,
NEBL-MLL, LASP1-MLL and MAML2-MLL displayed oncogenic
activities. Again, the MLL⁄ protein was sufﬁcient to cause focus for-
mation, however, with a slower kinetic than the other tested
constructs. Fortunately, a potent and MLL-speciﬁc SET domain
inhibitor has recently been developed by the group of Yali Dou
[22]. Thus, even if this mutant form of MLL displays oncogenic
features, future experiments may decipher whether an already
existing drug may block these oncogenic features.
In summary, we have successfully established a novel tool to
rapidly screen different MLL fusions in functional experiments,
allowing the prediction of oncogenic behaviour. This will assist
the investigation of other MLL fusions, and aid the identiﬁcation
of other constructs and fusion genes in an in vivo model setting
to monitor leukemogenic potential.
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